Lindbrook Capital’s Carisma Therapeutics CARM Stock Holding History

Lindbrook Capital’s Portfolio CARM Stock Details CARM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-500	Closed	-$14K	–	1400
2018 Q4	$14K	Buy	+500	New	+$15.9K	0.01%	725

Other funds holding CARM

KCM

Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

TRV GP Boston, Massachusetts $18.9M AUM 541.67% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

CHP

Castle Hook Partners New York $23.4B AUM 158.96% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Hikari Power Tokyo, Japan $1.15B AUM 5.31% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Lindbrook Capital's CARM Position: Q1 2019 in Review

Lindbrook Capital sold out of Carisma Therapeutics (CARM) in Q1 2019, closing a stake of 500 shares — an estimated $14K sold.

Lindbrook Capital first reported a position in CARM in Q4 2018 and held it in 1 quarter. The position peaked at $14K in Q4 2018. 48 funds tracked by Wall St. Rank hold CARM as of Q1 2019.

Lindbrook Capital reported no remaining Carisma Therapeutics position as of Q1 2019 after selling out during the quarter.
Lindbrook Capital sold 500 Carisma Therapeutics shares in Q1 2019, an estimated $14K.
Lindbrook Capital first reported a position in Carisma Therapeutics in Q4 2018 and held it in 1 quarter.
Lindbrook Capital's Carisma Therapeutics position peaked at $14K in Q4 2018.
48 funds tracked by Wall St. Rank held Carisma Therapeutics as of Q1 2019.

Based on Lindbrook Capital's 13F filing for Q1 2019, filed 23 Apr 2019.